vs
Crane NXT, Co.（CXT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Crane NXT, Co.的1.6倍（$772.1M vs $476.9M），Revvity净利率更高（12.7% vs 10.0%，领先2.8%），Crane NXT, Co.同比增速更快（19.5% vs 5.9%），过去两年Crane NXT, Co.的营收复合增速更高（23.3% vs 9.0%）
Crane NXT是一家总部位于美国康涅狄格州斯坦福德的工业产品企业，由理查德·特勒·克莱恩于1855年创立。曾是美国头部卫浴配件制造商，1990年出售卫浴业务后，自1960年起逐步转型为多元化控股集团，目前核心业务涵盖航空航天与电子、工程材料、流体处理、控制设备四大板块，服务化工等多个行业领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CXT vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$476.9M
营收增速更快
CXT
高出13.6%
5.9%
净利率更高
RVTY
高出2.8%
10.0%
两年增速更快
CXT
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $476.9M | $772.1M |
| 净利润 | $47.5M | $98.4M |
| 毛利率 | 42.4% | — |
| 营业利润率 | 16.7% | 14.5% |
| 净利率 | 10.0% | 12.7% |
| 营收同比 | 19.5% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $0.82 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CXTRVTY
| Q4 25 | $476.9M | $772.1M | ||
| Q3 25 | $445.1M | $698.9M | ||
| Q2 25 | $404.4M | $720.3M | ||
| Q1 25 | $330.3M | $664.8M | ||
| Q4 24 | $399.1M | $729.4M | ||
| Q3 24 | $403.5M | $684.0M | ||
| Q2 24 | $370.6M | $691.7M | ||
| Q1 24 | $313.6M | $649.9M |
净利润CXTRVTY
| Q4 25 | $47.5M | $98.4M | ||
| Q3 25 | $50.5M | $46.7M | ||
| Q2 25 | $24.9M | $53.9M | ||
| Q1 25 | $21.7M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $47.1M | $94.4M | ||
| Q2 24 | $41.6M | $55.4M | ||
| Q1 24 | $37.8M | $26.0M |
毛利率CXTRVTY
| Q4 25 | 42.4% | — | ||
| Q3 25 | 43.3% | 53.6% | ||
| Q2 25 | 41.7% | 54.5% | ||
| Q1 25 | 42.4% | 56.5% | ||
| Q4 24 | 45.2% | — | ||
| Q3 24 | 42.5% | 56.3% | ||
| Q2 24 | 43.4% | 55.7% | ||
| Q1 24 | 48.6% | 54.6% |
营业利润率CXTRVTY
| Q4 25 | 16.7% | 14.5% | ||
| Q3 25 | 18.4% | 11.7% | ||
| Q2 25 | 11.8% | 12.6% | ||
| Q1 25 | 11.3% | 10.9% | ||
| Q4 24 | 17.7% | 16.3% | ||
| Q3 24 | 18.6% | 14.3% | ||
| Q2 24 | 18.2% | 12.4% | ||
| Q1 24 | 17.7% | 6.8% |
净利率CXTRVTY
| Q4 25 | 10.0% | 12.7% | ||
| Q3 25 | 11.3% | 6.7% | ||
| Q2 25 | 6.2% | 7.5% | ||
| Q1 25 | 6.6% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 11.7% | 13.8% | ||
| Q2 24 | 11.2% | 8.0% | ||
| Q1 24 | 12.1% | 4.0% |
每股收益（稀释后）CXTRVTY
| Q4 25 | $0.82 | $0.86 | ||
| Q3 25 | $0.87 | $0.40 | ||
| Q2 25 | $0.43 | $0.46 | ||
| Q1 25 | $0.38 | $0.35 | ||
| Q4 24 | $1.00 | $0.77 | ||
| Q3 24 | $0.81 | $0.77 | ||
| Q2 24 | $0.72 | $0.45 | ||
| Q1 24 | $0.66 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $233.8M | $919.9M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $3.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.80× | — |
8季度趋势，按日历期对齐
现金及短期投资CXTRVTY
| Q4 25 | $233.8M | $919.9M | ||
| Q3 25 | $182.4M | $931.4M | ||
| Q2 25 | $152.5M | $991.8M | ||
| Q1 25 | $173.8M | $1.1B | ||
| Q4 24 | $165.8M | $1.2B | ||
| Q3 24 | $165.1M | $1.2B | ||
| Q2 24 | $175.5M | $2.0B | ||
| Q1 24 | $220.6M | $1.7B |
总债务CXTRVTY
| Q4 25 | $1.0B | — | ||
| Q3 25 | $834.3M | — | ||
| Q2 25 | $861.8M | — | ||
| Q1 25 | $541.1M | — | ||
| Q4 24 | $540.6M | — | ||
| Q3 24 | $638.2M | — | ||
| Q2 24 | $638.9M | — | ||
| Q1 24 | $639.6M | — |
股东权益CXTRVTY
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.2B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $989.8M | $7.9B | ||
| Q1 24 | $964.1M | $7.8B |
总资产CXTRVTY
| Q4 25 | $3.1B | $12.2B | ||
| Q3 25 | $2.9B | $12.1B | ||
| Q2 25 | $2.9B | $12.4B | ||
| Q1 25 | $2.4B | $12.4B | ||
| Q4 24 | $2.4B | $12.4B | ||
| Q3 24 | $2.4B | $12.8B | ||
| Q2 24 | $2.4B | $13.4B | ||
| Q1 24 | $2.1B | $13.4B |
负债/权益比CXTRVTY
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.66× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $105.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 2.23× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流CXTRVTY
| Q4 25 | $105.8M | $182.0M | ||
| Q3 25 | $92.0M | $138.5M | ||
| Q2 25 | $62.8M | $134.3M | ||
| Q1 25 | $-19.1M | $128.2M | ||
| Q4 24 | $81.1M | $174.2M | ||
| Q3 24 | $66.7M | $147.9M | ||
| Q2 24 | $56.8M | $158.6M | ||
| Q1 24 | $9.5M | $147.6M |
自由现金流CXTRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $78.7M | $120.0M | ||
| Q2 25 | $55.8M | $115.5M | ||
| Q1 25 | $-32.2M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | $53.5M | $125.6M | ||
| Q2 24 | $47.9M | $136.6M | ||
| Q1 24 | $-3.0M | $129.7M |
自由现金流率CXTRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 17.7% | 17.2% | ||
| Q2 25 | 13.8% | 16.0% | ||
| Q1 25 | -9.7% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | 13.3% | 18.4% | ||
| Q2 24 | 12.9% | 19.7% | ||
| Q1 24 | -1.0% | 20.0% |
资本支出强度CXTRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 3.0% | 2.6% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 4.0% | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | 3.3% | 3.3% | ||
| Q2 24 | 2.4% | 3.2% | ||
| Q1 24 | 4.0% | 2.7% |
现金转化率CXTRVTY
| Q4 25 | 2.23× | 1.85× | ||
| Q3 25 | 1.82× | 2.97× | ||
| Q2 25 | 2.52× | 2.49× | ||
| Q1 25 | -0.88× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 1.42× | 1.57× | ||
| Q2 24 | 1.37× | 2.87× | ||
| Q1 24 | 0.25× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXT
| Other | $260.9M | 55% |
| Products | $181.1M | 38% |
| Services | $34.9M | 7% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
